Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
University of California, Irvine
Immatics US, Inc.
Acepodia Biotech, Inc.
BioEclipse Therapeutics
Gilead Sciences
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
BGI, China
Genocea Biosciences, Inc.
GlaxoSmithKline